These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 11939604)

  • 1. Conditioning therapy with intravenous busulfan and cyclophosphamide (IV BuCy2) for hematologic malignancies prior to allogeneic stem cell transplantation: a phase II study.
    Andersson BS; Kashyap A; Gian V; Wingard JR; Fernandez H; Cagnoni PJ; Jones RB; Tarantolo S; Hu WW; Blume KG; Forman SJ; Champlin RE
    Biol Blood Marrow Transplant; 2002; 8(3):145-54. PubMed ID: 11939604
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dose modification protocol using intravenous busulfan (Busulfex) and cyclophosphamide followed by autologous or allogeneic peripheral blood stem cell transplantation in patients with hematologic malignancies.
    Williams CB; Day SD; Reed MD; Copelan EA; Bechtel T; Leather HL; Wingard JR; Abbott BL; Abhyankar S; McGuirk JP
    Biol Blood Marrow Transplant; 2004 Sep; 10(9):614-23. PubMed ID: 15319773
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravenous versus oral busulfan as part of a busulfan/cyclophosphamide preparative regimen for allogeneic hematopoietic stem cell transplantation: decreased incidence of hepatic venoocclusive disease (HVOD), HVOD-related mortality, and overall 100-day mortality.
    Kashyap A; Wingard J; Cagnoni P; Roy J; Tarantolo S; Hu W; Blume K; Niland J; Palmer JM; Vaughan W; Fernandez H; Champlin R; Forman S; Andersson BS
    Biol Blood Marrow Transplant; 2002; 8(9):493-500. PubMed ID: 12374454
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acute safety and pharmacokinetics of intravenous busulfan when used with oral busulfan and cyclophosphamide as pretransplantation conditioning therapy: a phase I study.
    Andersson BS; Madden T; Tran HT; Hu WW; Blume KG; Chow DS; Champlin RE; Vaughan WP
    Biol Blood Marrow Transplant; 2000; 6(5A):548-54. PubMed ID: 11071260
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes.
    Russell JA; Tran HT; Quinlan D; Chaudhry A; Duggan P; Brown C; Stewart D; Ruether JD; Morris D; Glick S; Gyonyor E; Andersson BS
    Biol Blood Marrow Transplant; 2002; 8(9):468-76. PubMed ID: 12374451
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of safety and pharmacokinetics of administering intravenous busulfan in a twice-daily or daily schedule to patients with advanced hematologic malignant disease undergoing stem cell transplantation.
    Fernandez HF; Tran HT; Albrecht F; Lennon S; Caldera H; Goodman MS
    Biol Blood Marrow Transplant; 2002; 8(9):486-92. PubMed ID: 12374453
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Busulfan systemic exposure relative to regimen-related toxicity and acute graft-versus-host disease: defining a therapeutic window for i.v. BuCy2 in chronic myelogenous leukemia.
    Andersson BS; Thall PF; Madden T; Couriel D; Wang X; Tran HT; Anderlini P; de Lima M; Gajewski J; Champlin RE
    Biol Blood Marrow Transplant; 2002; 8(9):477-85. PubMed ID: 12374452
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Busulfan-cyclophosphamide versus cyclophosphamide-busulfan as conditioning regimen before allogeneic hematopoietic cell transplantation: a prospective randomized trial.
    Seydoux C; Medinger M; Gerull S; Halter J; Heim D; Chalandon Y; Levrat SM; Schanz U; Nair G; Ansari M; Simon P; Passweg JR; Cantoni N
    Ann Hematol; 2021 Jan; 100(1):209-216. PubMed ID: 33098041
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modified busulfan and cyclophosphamide conditioning regimen for allogeneic hematopoietic stem cell transplantation in the treatment of patients with hematologic malignancies.
    Zhao XF; Mao XF; Wan DM; Liu W
    Transplant Proc; 2014 Jun; 46(5):1531-5. PubMed ID: 24935325
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Phase I study of gemtuzumab ozogamicin (GO) in combination with busulfan and cyclophosphamide (Bu/Cy) and allogeneic stem cell transplantation in children with poor-risk CD33+ AML: a new targeted immunochemotherapy myeloablative conditioning (MAC) regimen.
    Satwani P; Bhatia M; Garvin JH; George D; Dela Cruz F; Le Gall J; Jin Z; Schwartz J; Duffy D; van de Ven C; Foley S; Hawks R; Morris E; Baxter-Lowe LA; Cairo MS
    Biol Blood Marrow Transplant; 2012 Feb; 18(2):324-9. PubMed ID: 22079471
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of total body irradiation vs busulfan in combination with cyclophosphamide as conditioning for unrelated stem cell transplantation in CML patients.
    Kröger N; Zabelina T; Krüger W; Renges H; Stute N; Kabisch H; Jaburg N; Löliger C; Krüll A; Zander AR
    Bone Marrow Transplant; 2001 Feb; 27(4):349-54. PubMed ID: 11313663
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dose-escalated treosulphan in combination with cyclophosphamide as a new preparative regimen for allogeneic haematopoietic stem cell transplantation in patients with an increased risk for regimen-related complications.
    Beelen DW; Trenschel R; Casper J; Freund M; Hilger RA; Scheulen ME; Basara N; Fauser AA; Hertenstein B; Mylius HA; Baumgart J; Pichlmeier U; Hahn JR; Holler E
    Bone Marrow Transplant; 2005 Feb; 35(3):233-41. PubMed ID: 15592494
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic drug monitoring for either oral or intravenous busulfan when combined with pre- and post-transplantation cyclophosphamide.
    Lombardi LR; Kanakry CG; Zahurak M; Durakovic N; Bolaños-Meade J; Kasamon YL; Gladstone DE; Matsui W; Borrello I; Huff CA; Swinnen LJ; Brodsky RA; Ambinder RF; Fuchs EJ; Rosner GL; Jones RJ; Luznik L
    Leuk Lymphoma; 2016; 57(3):666-75. PubMed ID: 26292764
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Individualizing high-dose oral busulfan: prospective dose adjustment in a pediatric population undergoing allogeneic stem cell transplantation for advanced hematologic malignancies.
    Tran HT; Madden T; Petropoulos D; Worth LL; Felix EA; Sprigg-Saenz HA; Choroszy M; Danielson M; Przepiorka D; Chan KW
    Bone Marrow Transplant; 2000 Sep; 26(5):463-70. PubMed ID: 11019834
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Allogeneic stem cell transplantation (BMT) for AML and MDS following i.v. busulfan and cyclophosphamide (i.v. BuCy).
    Andersson BS; Gajewski J; Donato M; Giralt S; Gian V; Wingard J; Tarantolo S; Fernandez H; Hu WW; Blume K; Kashyap A; Forman SJ; Champlin RE
    Bone Marrow Transplant; 2000 May; 25 Suppl 2():S35-8. PubMed ID: 10933185
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravenous busulfan-cyclophosphamide as a preparative regimen before allogeneic hematopoietic stem cell transplantation for adult patients with acute lymphoblastic leukemia.
    Tang W; Wang L; Zhao WL; Chen YB; Shen ZX; Hu J
    Biol Blood Marrow Transplant; 2011 Oct; 17(10):1555-61. PubMed ID: 21549217
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Allogeneic hematopoietic stem-cell transplantation for acute myeloid leukemia in remission: comparison of intravenous busulfan plus cyclophosphamide (Cy) versus total-body irradiation plus Cy as conditioning regimen--a report from the acute leukemia working party of the European group for blood and marrow transplantation.
    Nagler A; Rocha V; Labopin M; Unal A; Ben Othman T; Campos A; Volin L; Poire X; Aljurf M; Masszi T; Socie G; Sengelov H; Michallet M; Passweg J; Veelken H; Yakoub-Agha I; Shimoni A; Mohty M
    J Clin Oncol; 2013 Oct; 31(28):3549-56. PubMed ID: 23980086
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Busulfex (i.v. BU) and CY regimen before SCT: Japanese-targeted phase II pharmacokinetics combined study.
    Kim SW; Mori SI; Tanosaki R; Fukuda T; Kami M; Sakamaki H; Yamashita T; Kodera Y; Terakura S; Taniguchi S; Miyakoshi S; Usui N; Yano S; Kawano Y; Nagatoshi Y; Harada M; Morishima Y; Okamoto S; Saito AM; Ohashi Y; Ueda R; Takaue Y
    Bone Marrow Transplant; 2009 Apr; 43(8):611-7. PubMed ID: 19011665
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic targeting of intravenous busulfan reduces conditioning regimen related toxicity following allogeneic hematopoietic cell transplantation for acute myelogenous leukemia.
    Pidala J; Kim J; Anasetti C; Kharfan-Dabaja MA; Nishihori T; Field T; Perkins J; Perez L; Fernandez HF
    J Hematol Oncol; 2010 Oct; 3():36. PubMed ID: 20925957
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Efficacy and toxicity of intravenous busulfan-based conditioning before allogeneic peripheral blood stem cell transplantation for leukemia].
    Tong XZ; Xu DR; Zou WY; Li J; Luo SK; Peng AH; Zhang GC; Zheng D
    Ai Zheng; 2007 Aug; 26(8):914-8. PubMed ID: 17697559
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.